These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 15750492)
1. Drug fiasco highlights need for more openness. Pollard T Br J Community Nurs; 2005 Jan; 10(1):5. PubMed ID: 15750492 [No Abstract] [Full Text] [Related]
2. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). Cotter J; Wooltorton E CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921 [No Abstract] [Full Text] [Related]
3. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Fendrick AM Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263 [No Abstract] [Full Text] [Related]
4. Cox-2 inhibitors: still no decisive action. Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408 [TBL] [Abstract][Full Text] [Related]
14. Rofecoxib, Merck, and the FDA. Villalba L; Witter J N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745 [No Abstract] [Full Text] [Related]
15. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related]
16. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Collantes-Estevez E; Fernandez-Perez C Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477 [TBL] [Abstract][Full Text] [Related]
17. Learning the value of drugs--is rofecoxib a regulatory success story? Eisenberg RS N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222 [No Abstract] [Full Text] [Related]
18. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Couzin J Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258 [No Abstract] [Full Text] [Related]